Home  >  News
Marketing + Font Resize -

Zydus gets US FDA tentative marketing nod for Pregabalin capsules

Our Bureau, Mumbai
Friday, December 1, 2017, 13:10 Hrs  [IST]

Zydus Pharmaceutical (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the tentative approval from the US FDA to market Pregabalin capsules in strengths of 25 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.

Pregabalin is used for management of certain kinds of seizures, neuropathic pain (never pain) and fibromyalgia. It will be manufactured at the group's formulation manufactured facility at Moraiya, Ahmedabad.

The group now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CPhI-WW-Banners-150X60-120618-anim-v2
pharmalytica_150x60_2018
CPhI_MEA_Banner_150x60_2018
150X60px_biowavers
IPE_2018_Banner_150X60
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |